SCR-LIP-000588 · Claim · machine-readable JSON →
Lipedema prevalence estimates vary widely and remain uncertain, partly because of underdiagnosis and the lack of validated diagnostic criteria.
General proposition consolidated from 2 earlier single-paper claims; each study's own result is shown as its finding.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- very low (GRADE)
- Evidence
- 3 source(s)
- Answers
- 1 question(s)
- Dates
- 2026-11-20 → 2026-11-20
Structured evidence, machine-compiled — not a verdict.
Evidence over time
Evidence (3)
- Lipedema: A Call to Action! — Buso et al. (2019) ✓ verified — consistent · review · 2019 · reading confidence: high
“Prevalência mínima: 1:72.000 na população geral (Child et al.), considerado subestimação — estudo alemão com 62 mulheres profissionais detectou lipedema em 39% (todos os estágios), 9,7% para apresentação moderada a grave”
Review cites a minimum prevalence of 1:72,000 in the general population, considered an underestimate, versus 39% (9.7% moderate-severe) in a German sample of 62 professional women.
This narrative review explicitly states that lipedema is underdiagnosed and misdiagnosed, and calls for increased awareness and better understanding of its clinical presentation to improve diagnosis, directly supporting the affirmative dire - Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025) ✓ verified — consistent · review · 2025 · reading confidence: high
“Prevalência estimada de 6–11% em mulheres na população geral; prevalência mundial ~10% — subestimada por ausência de código ICD-10 nos EUA e falta de biomarcador diagnóstico validado”
Review gives estimated prevalence of 6-11% in women (worldwide about 10%), considered underestimated due to absent ICD-10 code in the US and no validated diagnostic biomarker.
This systematic review directly addresses underrecognition and diagnostic challenges in lipedema, supporting the affirmative direction of the question, though it does not specifically evaluate screening tools. - Lipedema Research—Quo Vadis? — Ernst et al. (2022) ✓ verified — consistent · review · 2022 · reading confidence: high
“Prevalência mundial estimada em 11% entre mulheres — dado ampliado por subdiagnóstico, mas com limitação diagnóstica reconhecida pelos autores Incidência familiar em 15% de familiares femininas de primeiro grau”
Review cites an estimated 11% worldwide prevalence in women with acknowledged diagnostic limitation, and states true prevalence and incidence remain poorly defined.
This narrative review provides contextual background on lipedema's history, affected population (women), and clinical characteristics, but does not report specific prevalence or incidence data, making it contextually relevant but not direct
Context (PECO)
Answers these questions
Gaps & caveats
Change log
- 2026-11-20 — created_by_consolidation · general proposition consolidated from SQ-LIP-000002